212
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Adherence to Tumor Board Recommendations in the Treatment of Patients with Hepatocellular Carcinoma

ORCID Icon, , , &
Pages 1531-1540 | Received 09 Feb 2023, Accepted 06 Apr 2023, Published online: 31 May 2023

References

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
  • Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemporary Oncol. 2018;22(3):141–150. doi:10.5114/wo.2018.78941
  • Siddique O, Yoo ER, Perumpail RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma. J Multidiscip Healthc. 2017;10:95. doi:10.2147/JMDH.S128629
  • Llovet JM, Brú C, Bruix J Prognosis of hepatocellular carcinoma: the BCLC staging classification. Paper presented at: Seminars in liver disease; 1999.
  • Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2021:53.
  • Gish RG, Lencioni R, Di Bisceglie AM, Mazzaferro V. Role of the multidisciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2012;6(2). 173–185. doi:10.1586/egh.11.105
  • Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–1964. doi:10.1053/j.gastro.2017.02.040
  • Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723–750. doi:10.1002/hep.29913
  • Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550. doi:10.1200/JCO.2014.57.9151
  • Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-0
  • Therneau T. A package for survival analysis in S. R Package Version. 2015;2(7):435.
  • Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014;21(4):1287–1295. doi:10.1245/s10434-013-3413-8
  • Taylor C, Munro AJ, Glynne-Jones R, et al. Multidisciplinary team working in cancer: what is the evidence?. BMJ. 2010;340(mar23 2):c951–c951. doi:10.1136/bmj.c951
  • Gashin L, Tapper E, Babalola A, et al. Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. HPB. 2014;16(11):1009–1015. doi:10.1111/hpb.12280
  • Charriere B, Muscari F, Maulat C, et al. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings. J Surg Oncol. 2017;115(3):330–336. doi:10.1002/jso.24500
  • Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020;72(6):2206–2218. doi:10.1002/hep.31187